| 6.48 -0.29 (-4.28%) | 01-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.24 |
1-year : | 8.69 |
| Resists | First : | 7.06 |
Second : | 7.44 |
| Pivot price | 7.01 |
|||
| Supports | First : | 6.44 |
Second : | 5.35 |
| MAs | MA(5) : | 6.78 |
MA(20) : | 6.98 |
| MA(100) : | 7.03 |
MA(250) : | 7.21 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 11.4 |
D(3) : | 20.5 |
| RSI | RSI(14): 35.6 |
|||
| 52-week | High : | 9.35 | Low : | 5.78 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ MDXG ] has closed below the lower bollinger band by 16.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ MDXG ] is to continue within current trading range. Bollinger Bands are 0.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 6.8 - 6.85 | 6.85 - 6.89 |
| Low: | 6.33 - 6.39 | 6.39 - 6.43 |
| Close: | 6.4 - 6.49 | 6.49 - 6.56 |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
Fri, 26 Dec 2025
Harbor Capital Advisors Inc. Cuts Holdings in MiMedx Group, Inc $MDXG - MarketBeat
Mon, 22 Dec 2025
MiMedx Group, Inc. Partners with Regen Lab USA LLC to Distribute RegenKit®-Wound Gel in the U.S. - Quiver Quantitative
Mon, 22 Dec 2025
MIMEDX Enters into Exclusive U.S. Distribution Agreement for RegenKit®-Wound Gel - GlobeNewswire
Sat, 20 Dec 2025
With 47% stake, MiMedx Group, Inc. (NASDAQ:MDXG) seems to have captured institutional investors' interest - Yahoo Finance
Fri, 19 Dec 2025
MiMedx Group, Inc. Announces New Research Supporting Immunomodulatory Effects of Amniotic Membrane Allografts - Quiver Quantitative
Wed, 17 Dec 2025
Mizuho Maintains MiMedx Group (MDXG) Outperform Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 148 (M) |
| Shares Float | 110 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 71.8 (%) |
| Shares Short | 4,440 (K) |
| Shares Short P.Month | 4,470 (K) |
| EPS | 0.27 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.61 |
| Profit Margin | 10.3 % |
| Operating Margin | 19.5 % |
| Return on Assets (ttm) | 11.9 % |
| Return on Equity (ttm) | 19.4 % |
| Qtrly Rev. Growth | 35.2 % |
| Gross Profit (p.s.) | 2.17 |
| Sales Per Share | 2.65 |
| EBITDA (p.s.) | 0.46 |
| Qtrly Earnings Growth | 113.8 % |
| Operating Cash Flow | 68 (M) |
| Levered Free Cash Flow | 51 (M) |
| PE Ratio | 24 |
| PEG Ratio | 0 |
| Price to Book value | 4.02 |
| Price to Sales | 2.43 |
| Price to Cash Flow | 14.14 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|